Breaking News

Xencor, Pfizer Enter Antibody Tech Pact

Pfizer has entered into a technology license and evaluation agreement with Xencor, Inc. to optimize its therapeutic monoclonal antibodies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer has entered into a technology license and evaluation agreement with Xencor, Inc. to optimize its therapeutic monoclonal antibodies. Pfizer will apply Xencor’s Xtend antibody half-life prolongation technology and XmAb ADCC enhancing technology for to its antibody drug candidates. Pfizer will have access to Xencor’s antibody technology for a non-exclusive research period for use in several of its discovery projects. Pfizer has also taken a commercial license to Xencor’s technology for o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters